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Abstract
Objective: To identify nutritional and weight gain limitations associated with retinopathy of prematurity (ROP) severity
among very preterm newborns.
Patients and Methods: 1180 infants ,28 weeks GA at birth with ROP examination results were grouped and analyzed by
quartile of weekly total calorie, carbohydrate, protein, and lipid intake, as well as growth velocity between postnatal days 7
and 28 (adjusted for GA and birth weight Z-score). ROP was categorized by development of no, mild (,prethreshold), type
2, or type 1 ROP, as well as markers of ROP severity including stage 3 ROP, zone 1 disease, and plus disease. Associations
between nutritional intake and ROP severity were compared.
Results: Greater risk for Type 1 ROP (risk/95% confidence intervals) was found for infants with lowest quartile receipt of
lipids (2.1/1.1, 3.8), total calories (2.2/1.4, 3.6), and carbohydrates (1.7/1.1, 2.9). Development of zone 1 ROP was associated
with lipid or total calorie intake in the lowest quartile, and development of stage 3 ROP was associated with lowest quartile
of total calorie intake. Growth velocity in the lowest quartile was associated with increased risk of any ROP, including type 1
ROP.
Conclusion: The risk of developing severe ROP in extremely premature infants might be reduced by improving nutritional
support, specifically targeting lipids and total calories, and perhaps by improving weight gain.
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Introduction
Retinopathy of prematurity (ROP), a neovascular disease of the
retina found in very premature infants, can result in life-long visual
limitations. Identifying the antecedents of ROP provides addi-
tional information on relevant pathogenic mechanisms involved
and has the potential to help reduce the occurrence of this disease
and its consequences. [1].
Early nutritional support is a critical part of optimizing growth
and development in the premature infant, including normal retinal
vascularization. Insulin-like growth factor (IGF)-1 is important for
normal infant growth [2–4] and retinal vascularization, [5–8] and
is regulated by total caloric and protein intake. [2] Lipid emulsions
are an important part of nutritional support; omega-3 long chain
polyunsaturated fatty acids have been shown to suppress
inflammatory factors and contribute to antiangiogenic and
neuroprotective mechanisms in the retina. [9–13] Early weight
gain is an important marker of nutritional status, and poor
postnatal weight gain has been associated with an increased risk of
severe ROP. [14–17] Algorithms have been developed that
employ postnatal weight gain and IGF levels to predict develop-
ment of severe ROP. [18,19].
Premature infants enrolled in the ELGAN (extremely low
gestational age newborn) Study had assessments of nutritional
support (carbohydrate, protein, lipids, and total calories) and
weight measurements during the first 28 days of life. We evaluated
the relationships between components of early nutritional support
and weight gain with markers of ROP severity in this at-risk
population.
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Sample
The ELGAN Study, a prospective cohort study designed to
identify characteristics and exposures that increase the risk of
structural and functional neurologic disorders, enrolled 1506
extremely low gestational age newborns (birth between 23 and 27
6/7 weeks of gestation) at one of 14 participating institutions
between 2002–2004. [20] The enrollment and consent processes
were approved by the individual institutional review boards, and
research conducted according to the principles expressed in the
Declaration of Helsinki. Written informed consent was obtained
from the parents and/or legal guardians of all infants enrolled in
the study.
Of these newborns, 1187 had their weight recorded on days 7
and 28, as well as nutrition information collected on days selected
for analysis (days 3, 7, 14, and 21). The gestational age, birth
weight, and other perinatal characteristics of 1064 of these 1187
infants are presented elsewhere. [21] Results of retinal examina-
tions were available for 1180 of these infants. The enrollment and
consent processes were approved by the individual institutional
review boards.
Infant Characteristics
Gestational age (GA) estimates were based on a hierarchy of the
quality of available information with estimates based on the dates
of embryo retrieval or intrauterine insemination or fetal
ultrasound before the 14
th week of gestation (62%) as the most
desirable. Next most desirable in sequential order were estimates
based on a fetal ultrasound at 14 or more weeks of gestation (29%),
last menstrual period without fetal ultrasound (7%), and GA
recorded in the log of the NICU (1%).
Nutrition Data
Detailed nutritional data were collected daily for the first 7
postnatal days, then weekly on days 14, 21, and 28. [22] Type and
volume of intravenous solutions (including composition of
parenteral nutrition) as well as type and volume of enteral feedings
(including caloric additives) were routinely recorded. All nutri-
tional practice variables summarize nutritional intake from both
parenteral and enteral routes.
Nutrient information was calculated for the macronutrients
protein, carbohydrates, and fats. These totals were calculated by
multiplying the daily total volume of the diet by the macronutrient
content as specific on the nutritional label for all formula types and
nutritional additives, such as powdered proteins or fat oils. For
breast milk, we calculated nutritional intake using values for
mature milk (Ross Neonova system, version 4.5, 1999) since by 14
days the composition of preterm milk and term milk are similar.
Although human milk composition can be very dynamic, it was
not feasible in this study to capture the composition of every breast
milk sample provided to the infants.
Total kilocalories per day were divided by the birth weight until
the birth weight was surpassed, then by the weight on the day the
nutritional information was collected. The final units for the
macronutrient calculations were kcals/kg/day. For analysis, we
categorized the mean total nutrient (g/kg/day) and mean total
calories (kcal/kg/day) on each of four selected days (3, 7, 14 and
21) into quartiles.
Weight Change
Body weight was measured each day in the first postnatal week,
then on days 14, 21 and 28. The rate in growth is expressed as g/
kg/day. Because ELGANs tend to lose weight during the first
postnatal week [23] our measure of weight gain was calculated for
the interval between days 7 and 28 [((wt28-wt7)/wt7)/(28-7)
10006g/kg/day]. We categorized this measure of weight gain into
quartiles.
Eye Examinations
Retinal examinations were performed by ophthalmologists
experienced in ROP screening. Participating ophthalmologists
helped prepare a manual and data collection form, and then
participated in efforts to minimize observer variability. Definitions
of terms were those accepted by the International Committee for
Classification of ROP. [24] In keeping with guidelines, [25–26]
the first ophthalmologic examination was within the 31
st to 33
rd
post-menstrual week. Follow-up exams were as clinically indicated
until normal vascularization began in zone III.
For purposes of discussion, prethreshold ROP is defined as any
ROP in zone 1, stage 2 ROP in zone 2 with plus disease, or stage 3
ROP in zone 2 with or without plus disease. Prethreshold ROP is
designated as type 1 or type 2 ROP, [27] as follows:
Type 1 ROP:
N zone I, any stage ROP with plus disease;
N zone I, stage 3 ROP without plus disease; or
N zone II, stage 2 or 3 ROP with plus disease.
Type 2 ROP
N zone I, stage 1 or 2 ROP without plus disease or
N zone II, stage 3 ROP without plus disease.
During the study period, criteria for treatment of ROP varied,
due to participation in the Early Treatment for Retinopathy of
Prematurity (ETROP) randomized trial, or due to subsequent
changes in treatment recommendations [27–28]. We did not
evaluate need to treat as a separate indicator of severity, since
some eyes of infants in the ELGAN study received treatment for
high-risk prethreshold or type 1 ROP, while others received
treatment only when threshold ROP developed. Threshold ROP
Table 1. Sample description.
Yes No
Enrolled 1506
Weight measured: on days 7 and 28 1187 319
Nutrition information available* 1187 0
ROP diagnoses available 1180 7
No ROP (this is the referent group) 304
Therapy Mild 517
oriented Type 2 203
Type 1 156
Stage 1 260
2 271
$3 345
Zone III 52
II 765
I8 9
Plus disease Yes 131
*collected on selected days: 3, 7, 14, and 21.
doi:10.1371/journal.pone.0064325.t001
NutWtGain ROP
PLOS ONE | www.plosone.org 2 May 2013 | Volume 8 | Issue 5 | e64325Figure 1. Box and whiskers displays of total carbohydrate, protein, and fat (g/kg/day), total calories (kcal/kg/day), and growth
velocity (g/kg/day) among children classified by ROP severity.
doi:10.1371/journal.pone.0064325.g001
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ROP with plus disease in zone 1 or 2, so all cases previously
designated as threshold or near threshold ROP are included in the
current classification of type 1 ROP.
In this analysis, we categorized ROP severity in four ways: no
ROP, mild ROP (,prethreshold), type 2 ROP, and type 1 ROP.
Additional markers of severity were noted as$stage 3 ROP, zone I
disease, and presence of plus disease. The comparison groups in
these analyses include infants with no or mild ROP.
Statistical Analyses
We evaluated two hypotheses. First, infants who received
nutrition (i.e., protein, carbohydrate, fat and total calories) in the
lowest quartile are not at increased risk of any measure of ROP
severity. Second, infants in the lowest quartile of weight gain are
not at increased risk of any indicator of ROP severity.
We evaluated these hypotheses in two ways. One set of analyses
was characterized by logistic regression models of each level of
severity compared to the referent group of children who did not
have any ROP. To account for the possibility that infants born at a
particular hospital are more like each other than like infants born
at other hospitals, a hospital cluster term was included in all of
these models. [29].
Because each level of severity is mutually exclusive and each is
appropriately compared to the same referent group of infants
without any ROP, we also created multinomial (aka polytomous or
polychotomous) logistic regression models. [30,31] Multinomial
models do not allow a cluster term to be included.
All models adjusted for gestational age category (23–24, 25–26,
27 weeks), and birth weight Z-score category (,22, $2 2
to,21, $2 1t o0 ,$0). We calculated odds ratios (and 95%
confidence intervals) with the aid of the logistic regression models.
By and large, the two sets of analyses provided similar findings.
For economy of space we present only results obtained with the
multinomial models.
Results
Of the 1180 infants studied, 876 (74%) developed ROP
(Table 1). Thirty percent (359/1180) developed prethreshold
ROP, and 13% (156/1180) developed Type 1 ROP. ROP$ stage
3 developed in 345 infants; zone 1 disease was present in 89
infants.
Figure 1 shows the distribution of mean total nutrients and
calories received on days of life 3, 7, 14 and 21. Not only was the
median amount of carbohydrates received by children who had no
ROP higher than those who developed ROP, but the more severe
the ROP, the lower the median. A similar pattern was seen for
median total fat, and mean total calories, but not for median total
protein. In contrast to the linear relationships between the levels of
some nutrients and ROP severity, no such pattern was seen
between weight gain between days 7 and 28 and ROP severity.
Table 2 displays the risk of ROP for infants whose receipt of
each nutrient or calorie intake was in the lowest quartile, adjusted
for gestational age and birth weight Z-score. Increased risk of type
1 ROP was found for infants in the lowest quartile for
carbohydrate, fat, and total calorie intake. Increased risk of$stage
3 ROP was found for infants in the lowest quartile of total calorie
intake, and increased risk of zone 1 ROP was found for infants in
the lowest quartile of fat or total calorie intake. Receipt of low
amounts of protein was not associated with appreciably increased
risk of any ROP severity.
Unlike Table 2, Table 3 shows the three lower quartiles for
growth velocity, which provided an opportunity to see if a dose-
response characterized the findings. Weight gain in the lowest
quartile was associated with increased risk of all stages of ROP,
including type 1ROP. Less limited weight gains were not
associated with increased risk of any severity level of ROP.
Males and females did not differ in nutritional intake, growth
velocity, or ROP risk.
Table 2. The risks (and 95% confidence intervals) of the ROP
level identified on the left among infants whose receipt of the
nutrient or calories at the top of each column was in the
lowest quartile relative to the risk among children whose
receipt was in the top 3 quartiles.
Retinopathy
of prematurity Lowest quartile
CHO Protein Fat Calories
Therapy Mild 1.5 (0.99, 2.2) 0.9 (0.6, 1.2) 1.7 (1.1, 2.6) 1.0 (0.7, 1.5)
oriented Type 2 1.9 (1.2, 3.0) 0.9 (0.6, 1.4) 2.9 (1.8, 4.8) 1.7 (1.1, 2.7)
Type 1 1.7 (1.1, 2.9) 1.1 (0.7, 1.8) 2.8 (1.7, 4.7) 2.2 (1.4, 3.6)
Stage 1 1.1 (0.7, 1.8) 1.1 (0.8, 1.6) 1.1 (0.7, 1.9) 0.8 (0.5, 1.3)
2 1.8 (1.1, 2.7) 0.7 (0.4, 1.00) 2.3 (1.4, 3.6) 1.2 (0.8, 1.9)
$3 2.0 (0.3, 3.1) 1.0 (0.7, 1.5) 3.2 (2.0, 5.0) 2.1 (1.4, 3.2)
Zone III 1.3 (0.6, 2.8) 1.8 (0.9, 3.3) 1.1 (0.5, 2.9) 1.1 (0.5, 2.4)
II 1.6 (1.1, 2.4) 0.8 (0.6, 1.1) 2.1 (1.4, 3.2) 1.3 (0.9, 1.8)
I 1.8 (0.99, 3.2) 1.4 (0.8, 2.5) 2.6 (1.4, 4.6) 2.2 (1.2, 3.8)
Plus Yes 1.1 (0.8, 1.7) 1.2 (0.8, 1.8) 1.4 (0.9, 2.0) 1.5 (0.98, 2.2)
These have been adjusted for gestational age and birth weight Z-score. Bolded
odds ratios are significant at the 0.05 level.
doi:10.1371/journal.pone.0064325.t002
Table 3. The risks (and 95% confidence intervals) of the ROP
level identified on the left among infants classified by the
quartile of their weight gain between days 7 and 28 relative to
the risk among children whose weight gain was in the highest
quartile.
Growth velocity quartile
Retinopathy of
prematurity Lowest Low middle Hi middle
Therapy Mild 1.9 (1.2, 3.0) 1.3 (0.8, 1.9) 1.3 (0.9, 2.0)
oriented Type 2 2.0 (1.2, 3.5) 1.2 (0.7, 2.0) 0.9 (0.5, 1.6)
Type 1 1.9 (1.1, 3.5) 0.8 (0.5, 1.5) 0.8 (0.5, 1.5)
Stage 1 1.9 (1.1, 3.1) 1.3 (0.8, 2.1) 1.2 (0.8, 1.9)
2 1.8 (1.1, 3.0) 1.2 (0.7, 1.9) 1.3 (0.8, 2.2)
$3 2.2 (1.4, 3.7) 1.1 (0.7, 1.7) 0.9 (0.6, 1.5)
Zone III 2.2 (0.9, 5.7) 2.2 (0.9, 5.2) 1.4 (0.6, 3.6)
II 2.0 (1.3, 3.0) 1.2 (0.8, 1.8) 1.2 (0.8, 1.8)
I 1.5 (0.8, 3.0) 0.5 (0.2, 1.1) 0.8 (0.4, 1.5)
Plus Yes 1.1 (0.7, 1.8) 0.8 (05, 1.4) 0.7 (0.4, 1.2)
These have been adjusted for gestational age and birth weight Z-score. Bolded
odds ratios are significant at the 0.05 level.
doi:10.1371/journal.pone.0064325.t003
NutWtGain ROP
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In this cohort of extremely low gestational age newborns, intake
of total calories, lipids, and carbohydrates in the lowest quartile,
measured on postnatal days 3,7,14, and 21, was associated with
increased risk of type 1 ROP. Similarly, infants with growth
velocity in the lowest quartile were at higher risk of developing any
ROP, including type 1 ROP. These findings raise the possibility
that improving the early nutrition of these infants may help
prevent development of sight-threatening ROP.
In a previous report from the ELGAN Study, the intake of
protein and fat were within the generally accepted dietary goals for
ELGANs, while the goals for intake of carbohydrate and total
calories were not achieved. [22] Controversy continues about what
nutritional targets should be in preterm newborns. [32–36] While
growth velocities were maintained above 15 mg/kg/day, most
infants had a weight Z-score on day 28 that was lower than at
birth. This might be viewed as an indicator of extra-uterine growth
failure. Not surprisingly, infants who received protein, fat, and
carbohydrate amounts in the lowest quartile on day 7 were more
likely than their peers to have growth velocity in the lowest
quartile. We do not know why delivery of these nutrients was
suboptimal. While it is possible to observe associations between
low nutrition and co-morbidities, determining whether the
suboptimal delivery of nutrients contributed to development of
ROP or whether co-morbidities caused the poor dietary intake is
beyond the scope of information collected for this study.
Receipt of higher amounts of intravenous fat emulsion (2 g/kg/
day; Intralipid) during the first week of life has been associated
with decreased rates of ROP. [9] Our observation that infants in
the lowest quartile for lipid intake were at increased risk of
prethreshold ROP supports this finding. The quantity but not
quality of lipid intake was recorded, so it is possible that some
newborns experienced lipid component deficiencies known to be
important for retinal vascular development and stability, such as
the omega-3 long chain polyunsaturated fatty acid docosahex-
aenoic acid (DHA). [12,37] Parenteral lipid supplements given in
the United States do not contain DHA, and the addition of DHA
to infant formula commenced near the beginning of this study
period (2002). Even those who received breast milk early did not
have amounts recorded or DHA concentration analyzed.
Poor postnatal weight gain is a predictor of severe ROP. [14–
19,38–41] The WINROP algorithm, which measures a cumula-
tive slowdown in weight gain, has a high sensitivity (90–100%) for
detecting infants at risk of developing prethreshold ROP. A caveat
to assessment of weight gain alone is the need to distinguish those
infants who have non-physiologic weight gain, such as weight gain
from body edema, hydrocephalus, or other causes. Infants who
develop proliferative ROP often have co-morbidities such as
bronchopulmonary dysplasia and necrotizing enterocolitis, which
might limit nutrition and weight gain. In light of the associations
between IGF-1 blood concentrations and weight gain as well as
ROP risk [5–8,18] it is possible that low weight gain is not in the
causal chain leading to ROP, but instead is merely an indicator of
IGF-1 concentration, which might be in the causal chain. While
IGF-1 concentration is unlikely to influence administration of
nutrients, it may influence utilization of existing nutrients.
Although many studies have reported low weight gain as a risk
factor for ROP (Table 4), and one clinical trial has assessed the
contribution of intravenous fat emulsions to reducing ROP risk,
this is the first observational study of suboptimal early nutrition as
a risk factor for indicator of ROP severity in ELGANs. We found
infants receiving the lowest quartile of lipid, carbohydrate, and
total calories to be at increased risk of type 1 ROP. Higher
amounts of lipid emulsion in the early days of postnatal life, in
addition to DHA supplementation, could theoretically reduce
ROP risk. Since higher amounts of IV lipid appear to be well
tolerated, and given the importance of DHA in retina and brain
development [42–46], this seems to be an important nutritional
component to target. Additionally, maximizing total caloric intake
to support early growth appears to show promise of reducing risk
of prethreshold ROP.
The strengths of this study include the large number of infants
studied, enrollment on the basis of well defined gestational age, a
protocol with standardized assessments, and prospective collection
of nutritional data. Additionally, ROP exams were performed by
experienced examiners and ROP data collection occurred in a
prospective and standardized fashion. Limitations include less than
Table 4. Characteristics of the eight studies that evaluated low weight gain as a risk factor for ROP.
Weight gain study
#
infants
Entry
criteria Weight analysis ROP severity Other risk factors
‘
Wallace et al. J AAPOS 2000 111 ,30 weeks Relative weight gain
(g/kg/d) through 6 weeks
. stage 3 RBC volume transfused; bacteremia
Allegaert et al. J AAPOS 2003 37 ,35 weeks or
,2000 g
Absolute weight gain
(g/d) through 6 weeks
Threshold SGA, BW ,25%ile
Hellstrom et al. Pediatrics 2009 317 ,32 weeks WINROP* $ stage 3
Fortes Filho et al. Graefes Arch Clin
Exp Ophthal 2009
317 ,32 weeks or
,1500 g
Low weight gain
(,51%) at 6 weeks
stage 3 or threshold
Hard et al. Arch Ophthalmol 2010 366 ,32 weeks WINROP* $ stage 3
Wu et al. 2010 Arch Ophthalmol 318 ,32 weeks WINROP* $prethreshold or$stage 3
Binenbaum et al. 2011 Pediatrics 367 ,1000 g PINT-ROP** . stage 3 or threshold
Wu et al. 2012 Arch Ophthalmol 1706 ,32 weeks WINROP* Type 1 ROP
VanderVeen et al. 1180 ,28 weeks Growth velocity between days
7 and 28***
type 2/type 1, $stage 3,
zone 1, plus disease
Birth weight Z-score; carbohydrate,
protein, and lipid intake in lowest quartile
‘Exclusive of birthweight and gestational age at birth.
*Online algorithm that calculates difference between expected ‘‘safe’’ weight gain and actual weight gain; an alarm occurs if the accumulated values exceed a limit.
15,16.
**Calculated probability of severe ROP based on risk score incorporating GA, BW, and weight gain rate (g/d).
***[10006((weight28-weight7)/weight7)/(28-7)]=g/kg/day.
doi:10.1371/journal.pone.0064325.t004
NutWtGain ROP
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nutrient delivery.
Conclusion
Low intake of lipids, carbohydrates, and total calories was
associated with increased risks of sight-threatening ROP in this
cohort of ELGANs. Together with previous reports that low
weight gain is also a risk factor for ROP, this finding suggests that
efforts to improve the nutritional intake and weight gain of the
most vulnerable newborns might reduce the burden of sight-
limiting ROP.
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